Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics has demonstrated a favorable growth trajectory with management projecting significant revenue increases for 2026, estimating $167 million in CAR-T sales, which marks a year-over-year growth of approximately 220%. Additionally, the company’s guidance for Aucatzyl revenues between $120 million and $135 million indicates a robust 60-80% year-over-year increase, driven by an expansion of its ATC network to over 80 locations. The positive outlook is further supported by improved sales margins anticipated from increased scale and a historic trend of revenue growth, particularly in light of recent advancements in clinical guidelines favoring bispecific therapies.

Bears say

Autolus Therapeutics PLC exhibits a negative financial outlook due to significant concerns regarding stagnant revenue growth, specifically a nearly 48% decline in stock value since July 2025, in stark contrast to the positive performance of the Nasdaq Biotechnology Index. The company's new product launch, Aucatzyl, faced manufacturing limitations and flat sales during mid-2025, primarily resulting from changes imposed by the Centers for Medicare and Medicaid Services. Additionally, potential risks related to clinical efficacy, safety concerns, regulatory challenges, and anticipated capital needs further exacerbate the financial instability reflected in the company’s performance.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.